Castle Biosciences, Inc. (NASDAQ: CSTL) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $1.0B. The Maz Rating grades it against the other companies in its sector.
Castle Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $32.98, Castle Biosciences, Inc. trades at 2.7x sales and 2.1x book value. Over the last twelve months it generated about $376M of revenue and a net loss of $24M. It runs a gross margin of 77.1%, an operating margin of -7.4% and a net margin of -6.1%. It shows return on equity of -4.9%, return on invested capital of -5.4% and a free cash flow yield of 0.4%. On the balance sheet: a debt-to-equity ratio of 0.08 and a current ratio of 5.28. Over the past 52 weeks the share price ranged from $17.72 to $44.28, with a beta of 0.95.
Castle Biosciences, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 11 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Castle Biosciences, Inc. (CSTL) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.97% / 30% · (Cash+Inv) / Mkt Cap (36m) 26.8% / 30% · Interest income / Revenue 2.44% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.97% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 26.8% / 33% · Receivables / Mkt Cap (36m) 5.03% / 49% · Interest income / Revenue 2.44% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.97% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 26.8% / 33.33% · Receivables / Mkt Cap (24m) 5.03% / 33.33% · Interest income / Revenue 2.44% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 1.78% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 48.8% / 33.33% · Receivables / Avg Assets (4Q) 8.21% / 33.33% · Interest income / Revenue 2.44% / 5% | Fail |
| FTSE | Debt / Total Assets 1.74% / 33.33% · (Cash+ST Inv) / Total Assets 47.9% / 33.33% · (Cash+Recv) / Total Assets 56.9% / 33.33% · Interest income / Revenue 2.44% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Castle Biosciences, Inc. (CSTL) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Castle Biosciences, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.44% of each dividend: Castle Biosciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.